Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1, and HER1 in humans). Panitumumab is manufactured by Amgen and marketed as Vectibix. It was originally developed by Abgenix Inc.
According to The UP TO DATE site, Panitumumab has been associated with skin rash, fatigue, nausea, diarrhea, fever, and decreased magnesium levels. Often, skin rash is noted in the sun-exposed parts of the body, such as the face or chest. Oral antibiotics may be needed for worsening skin rash, such as one accompanied by blisters and ulcers. Otherwise, topical steroid creams like hydrocortisone may help. Ocular toxicity or keratitis was observed in 16% of patients on panitumumab, usually necessitating the discontinuance of therapy. In clinical trials, 90% of patients had dermatological toxicities and 15% of those were severe. Because of this, panitumumab has a boxed warning cautioning patients. Skin toxicities were typically apparent two weeks after beginning treatment. More severe skin toxicities were associated with improved progression-free survival and overall survival. Pulmonary fibrosis and interstitial lung disease were observed in clinical trials.